link to RWJMS home page
Banner Image Here

Research

Abstract Listing

Abstracts Published

Aisner J, Dahlberg S, Rodgers JS, Aisner SC, Schiller JH: Interferon alpha + 13-cis-retinoic acid modulation of bcl-2 + paclitaxel for recurrent SCLC. Proc. Am Soc Clin Oncol 26:2008 (May 20 suppl; abstr 19048).

A. Chanan-Khan, M Gharibo, S Jaganath, N Munshi, K Anderson, D DePaolo, K Lee, K Miller, R Guild, S Zildjan and QuinA. Phase I Study of IMGN901 In Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma. ASH Abstract # 3689, 2008.

Stein MN, Knox B, Wesolowsky E, Levitt M, Moss R, Poplin E, Mehnert J, Gounder M, Goodin S, DiPaola R.  Phase I trial of patupilone and RAD001 in patients with advanced solid tumors.  J Clin Oncol 2009;15s:abstract 2529.

Karine Cohen-Solal, Leungkai Chan, Kim Merrigan, James Goydos and Michael Reiss. Linker domains of Smad2 and Smad3: A role in the resistance of melanoma cells to TGFβ-mediated tumor suppression? The 2009 Annual Retreat on Cancer Research in New Jersey, Piscataway, New Jersey, May 27, 2009.

Hirshfield, K.M., Use of SNPs as Prognostic Indicators in Cancer Outcomes. (2008) AACR Centennial Conference Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine. ED04-02.

Jager A., Hirshfield K., Hait WN, B. Haffty, Jin Ming Yang. The selective estrogen receptor down-regulator, fulvestrant, decreases MDM2 expression and enhances sensitivity of human breast carcinoma cells to chemotherapeutic drugs. (2009) AACR 100th Annual Meeting Abstracts, p. 280.

Jäger A, Hait WN, Toppmeyer D, Haffty B, Hirshfield K, Yang JM. Fulvestrant Decreases MDM2 Expression and Enhances Sensitivity of Human Breast Carcinoma Cells to Chemotherapeutic Drugs. (2009) Annual Retreat on Cancer Research.

Kostialik J, Hirshfield KM. Association of Polymorphic Variants in the Melatonin Receptor with Breast Cancer Phenotypes. (2009) Aresty, Rutgers University.

Rahim H, Levine A, Hirshfield KM. P53 Codon 72 Genotype is Linked to an Accelerated Age of Diagnosis in Caucasian Women with Estrogen Receptor Negative Invasive Ductal Carcinoma. (2009) Aresty, Rutgers University.

Rahim H, Kulkarni D, Toppmeyer D, Hirshfield KM. Effect of Reproductive Characteristics and BMI on Age of Diagnosis in Breast Cancer. (2009) Annual Retreat on Cancer Research.

Sreenath M, Vazquez A, Hirshfield KM.Tuberous sclerosis genes TSC1 and TSC2, and breast cancer risk. (2009) Annual Retreat on Cancer Research.

Kulkarni D, Vazquez A, Hu W, Sun Y, Toppmeyer D, Levine A, Hirshfield KM.  A Polymorphic Variant in MDM4 Associates with Accelerated Age of Onset of ER Negative Breast Cancer. (2009) Annual Retreat on Cancer Research. Oral presentation.

Lu-Yao GL, Albertsen P, Moore DF, Barry M, Zietman A, O’Leary M, Walker-Corkery B, Shih W, Lin Y, DiPaola RS, Yao SL.  Outcomes of conservatively managed localized prostate cancer.  2009 ASCO oral presentation.

Shao J, Albertson PC, Roberts CB,  Lin Y, Mehta AR, Stein MN, DiPaola RS, Lu-Yao GL  Risk Profiles and Treatment Patterns among Men with Prostate Specific Antigen below 4 in the USA. The 2009 Annual Retreat on Cancer Research in New Jersey, Piscataway, New Jersey, May 27, 2009.

Shao J, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, DiPaola RS, Lu-Yao GL. Contemporary profile of prostate cancer in the US. The 2009 Annual Retreat on Cancer Research in New Jersey, Piscataway, New Jersey, May 27, 2009.

Roberts CB; Shao Y; Mehta A; Stein MN, Moore D, Lu-Yao, GL.  Patterns and Correlates of Attempted Curative Therapy in Older Men with Clinically Low-Risk Localized Prostate Cancer. The 2009 Annual Retreat on Cancer Research in New Jersey, Piscataway, New Jersey, May 27, 2009.

Lu-Yao GL, Albertsen P, Moore D, Lin Y, Shih W, DiPaola RS, Yao S. Disease Trajectory of Screen-Detected Localized Prostate Cancer.  The 2009 Annual Retreat on Cancer Research in New Jersey, Piscataway, New Jersey, May 27, 2009. Oral presentation.

Parekh N, Lu-Yao GL.  Demographic and anthropometric determinants of insulin like growth factor-1; preliminary evidence from the third national health and nutrition examination survey (NHANES III) Experimental Biology April 2009.

Rothenberg ML, Poplin EA, Mehnert J, LoRusso P, Fox F, Schwartz J, Rowinsky E and Higano C.  Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of Phase 1 Studies of IMC-A12, a Recombinant Human Insulin-Like Growth Factor-I Receptor IgG1 Monoclonal Antibody, in Patients With Advanced Solid Malignancies EORTC-AACR-NCI 2008 meeting, Geneva, Switzerland.

Karantza-Wadsworth V, Stein M, Tan A, Mehnert J, Poplin E, Lin Y, White E, DiPaola RS.  Rationally designed treatment for solid tumors with MAPK pathway activation. J Clin Oncol 27:15s, 2009 (suppl; abstr 2532).

Stein MN, Knox B, Wesolowsky E, Levitt M, Moss R, Poplin E, Mehnert J, Gounder M, Goodin S, DiPaola R. Phase I trial of patupilone (P) and RAD001 in patients (pts) with advanced solid tumors. J Clin Oncol 27:15s, 2009 (suppl; abstr 2529).

Stein M. N., Knox B., Wesolowsky E., Levitt M. Moss R., Poplin E., Mehnert J., Bounder M., Goodin S., DiPaola R.; The Cancer Institute of New Jersey, New Brunswick, NJ.  “Phase I Trial of Patupilone (P) and RAD001 ® in Patients (pts) with Advanced Solid Tumors.  ASCO 2009.

Saraiya B., Karantza-Wadsworth V., Stein M. N., Chugh R., Mehnert J., Moss R., Lin Y., Poplin E.; The Cancer Institute of New Jersey, New Brunswick, NJ; University of Michigan Hospitals, Ann Arbor, MI.  “Phase I Study of Gemcitabine, Docetaxel and Imatinib in Refractory and Relapsed Solid Tumors.  ASCO 2009.

Tan A.R.1, Lin H.1, Gounder M.1, Gibbon D.1, Stein M.1,  Moss R.A.1, Karntz-Wadsworth V.1, Savkina N.1, Lin Y. 1, Egorin M.J.2, and Chen A.3.  1UMDNJ-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, NJ; 2University of Pittsburgh Cancer Institute, Pittsburgh, PA; 3Cancer Therapy Evaluation Program, Rockville, MD.  “Phase I Trial of ABT-888, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Cyclophosphamide (CPA) in Patients with Advanced Malignancy:  Preliminary Results.  New Jersey Commission on Cancer Research 2009 Annual Retreat, Piscataway, NJ, May 27, 2009.

Saraiya B, Karantza-Wadsworth V. Stein MN, Chugh R, Mehnert J, Moss R, Lin Y and Poplin E.  The Cancer Institute of New Jersey, New Brunswick, NJ; University of Michigan Hospitals, Ann Arbor, MI.  Phase I study of gemcitabine, docetaxel, and imatinib in refractory and relapsed solid tumors.  J Clin Oncol 27, 2009 (suppl; abstr e13538).

Stein MN, Knox B, Wesolowsky E, Levitt M, Moss R, Poplin E, Mehnert J, Gounder M, Goodin S, DiPaola R; Cancer Institute of New Jersey, New Brunswick, NJ.  Phase I trial of patupilone (P) and RAD001 in patients (pts) with advanced solid tumors.  J Clin Oncol 27:15s, 2009 (suppl; abstr 2529).

Karantza-Wadsworth V, Stein M, Tan A, Mehnert J, Poplin E, Lin Y, White E, DiPaola RS; The Cancer Institute of New Jersey, New Brunswick, NJ.  Rationally designed treatment for solid tumors with MAPK pathway activation.  J Clin Oncol 27:15s, 2009 (suppl; abstr 2532).

Rongrong Ge, Vidya Ganapathy, Yibin Kang, John McPherson, Jonathan M. Yingling, and Michael Reiss. Transforming Growth Factor β pathway antagonists inhibit human basal cell-like breast cancer metastases to lung and bone. Abstract. Era of Hope. 2008.

Saraiya, B., Poplin EA et al., Phase I study of Gemcitabine, Docetaxel and Imatinib in refractory and relapsed solid tumors 2009 ASCO Annual Meeting, Orlando, FL.

Saraiya, B., Gounder, M., Dutta, J., Saleem, A., Rajendra, R., Collazo, C., Zimmerman, L., Nazar, A., Gharibo, M., Schaar, D., Lin, Y., Shih, W., Aisner, J., Strair, R.K., and Rubin, E. H. (2008)  Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.  Anti-Cancer Drugs 19(4): 411-420.

Medina DJ, Gharibo, M, Savage P, Cohler A, Kuriyan M, Balsara B, Anand M, Schaar D, Krimmel T, Saggiomo K, Manago J, Talty, L, Dudek L, Grospe S, Rubin A, Strair RK.  (2008)  A Pilot Study of Allogeneic Cellular Therapy for Patients with Advanced Hematologic Malignancies. Leukemia Research 32(12): 1842-1848.

Strair RK, Gharibo M, Schaar D, Rubin A, Harrison J, Aisner J, Lin H-S, Lin Y, Goodell L, Anand M, Balsara B, Dudek L, Rabson A, Medina DJ. (2008)  Nuclear Factor-kappaB (NF-kB) modulation in patients undergoing induction chemotherapy for Acute Myelogenous Leukemia.  Clinical Cancer Research. 14(22): 7564-8.

Schaar, Dale G., Medina, Daniel J., Moore, Dirk F., Strair, Roger K. and Ting, Yi. (2009) miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation.  Exp. Hematology. 37(2): 245-55.

Tan A.R., Mekhail T., Edelman M.J., Iacono L.C., Messina M., and Trifan O.C. Phase I trial of ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies: updated safety and maximum tolerated dose. Eur J Cancer Suppl 2008; 6:131 (abstr 416) (Poster presentation).

Burstein H., Sun, Y., Tan, A.R., Dirix, L., Vermette, J., Powell, C., Zacharchuk, C., and Badwe, R.  Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients       with advanced HER2+ breast cancer.  Breast Cancer Res and Treat 2008; (abstr) (Oral presentation).

Hemminger L, Campbell J, Vig H, Toppmeyer D. BioCONECT(Biology and Cancer, ONline Education Connecting Teens): An innovative and interactive high school curriculum" selected for Oral presentation during the 137th APHA Annual Meeting (November 7-11, 2009) in Philadelphia, PA.

Jager A., Hirshfield K., Hait WN, Toppmeyer D, B. Haffty, JM Yang. The selective estrogen receptor down-regulator, fulvestrant, decreases MDM2 expression and enhances sensitivity of human breast carcinoma cells to chemotherapeutic drugs. (2009) AACR 100th Annual Meeting Abstracts, p. 280.

Jäger A, Hait WN, Toppmeyer D, Haffty B, Hirshfield K, Yang JM. Fulvestrant Decreases MDM2 Expression and Enhances Sensitivity of Human Breast Carcinoma Cells to Chemotherapeutic Drugs. (2009) Annual Retreat on Cancer Research.

Rahim H, Kulkarni D, Toppmeyer D, Hirshfield KM. Effect of Reproductive Characteristics and BMI on Age of Diagnosis in Breast Cancer. (2009) Annual Retreat on Cancer Research.

Kulkarni D, Vazquez A, Hu W, Sun Y, Toppmeyer D, Levine A, Hirshfield KM. A Polymorphic Variant in MDM4 Associates with Accelerated Age of Onset of ER Negative Breast Cancer. (2009) Annual Retreat on Cancer Research. Oral presentation.

Patrick-Miller L, Cummings S, Fetzer D, Schmidheiser H, Daly MB, Toppmeyer D, Olopade O, Bradbury AR. The disclosure of BRCA1/2 test results: Opinions of recipients of BRCA1/2 testing.  Breast Cancer Research and Treatment, 2098, 2008.

Patrick-Miller L, Cummings S, Fetzer D, Schmidheiser H, Daly MB, Toppmeyer D, Olopade O, Bradbury AR. Telephone disclosure of BRCA1/2 test results?  Telephone disclosure of BRCA1/2 test results? Experience and opinions of consumers and genetic counselors.   11th International Meeting on the Psychosocial Aspects of Genetic Testing for Hereditary Cancer, 2009.

 

Abstract Archive
Click Here to browse the Abstract Archive